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background: With an increasingly aging population, examination of outcomes of the treatment options for elderly patients with severe aortic 
stenosis (AS) is relevant.
methods: Patients >90 years from 4/2007-4/2013 who underwent surgical aortic valve replacement (SAVR) or transcatheter AVR (TAVR) for severe 
AS were analyzed. Demographics, operative outcomes and Kansas City Cardiomyopathy Questionnaire (KCCQ) were evaluated. Survival was compared 
to the Social Security Actuarial Lifetables 2009 and by treatment method.
results: 91 patients underwent AVR (27 SAVR; 64 TAVR). Mean age was 91.8±1.9 years; 51.6% were female. Mean STS predicted risk of mortality 
was 11.4±5.9% (9.1±4.1 SAVR; 12.3±6.3 TAVR). Operative mortality was 14.3% (14.8% SAVR; 14.1% TAVR). Observed-to-expected mortality ratio 
was 1.63 in SAVR and 1.14 in TAVR. Postoperative stroke rates were similar (3.7% SAVR; 3.1% TAVR, p=0.89). There was a higher incidence of new 
onset atrial fibrillation in SAVR (40.7% SAVR; 18.8% TAVR, p=0.03). Kaplan-Meier survival (Figure) shows restoration of survival to that of an age-
matched US population. Survival in the transfemoral TAVR and SAVR was statistically superior to transapical TAVR (p=0.03). Mean KCCQ scores 
increased from baseline to 1 year (45.6-71.9, p<0.001, SAVR; 42.1-69.0, p=0.009, TAVR).
conclusions: Functional outcomes as measured by KCCQ improved significantly. With acceptable risk, treatment of AS restores normal life 
expectancy and should be considered in this population.
 
